共 3 条
[1]
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2005, 23 (16)
:3676-3685
[2]
Buzdar AU, 2003, BREAST CANCER RES TR, V82, pS69
[3]
WOLFF AC, 2003, P AN M AM SOC CLIN, V22, pA18